-
08:46:36 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

TEVA - Teva- Pharmaceutical Industries Ltd.

04/29/21 4:18 PM
NYSE : TEVA
Teva Announces the Launch of the First Generic Version of Absorica(R) (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced its launch of the first available 10 mg, 20 mg, 25 mg, 30 mg, 35 mg and 40 mg strength generic version of Absorica (R)1 (isotretinoin) capsules for the treatment of severe recalcitrant
RHEA-AI
neutral
04/27/21 8:00 AM
NYSE : TEVA
Teva to Present New Analyses of AUSTEDO(R) (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced four new posters examining long-term analyses of AUSTEDO (R) (deutetrabenazine) tablets and clinical outcome measures in schizophrenia will be presented at the upcoming 2021 American
RHEA-AI
neutral
04/23/21 11:09 AM
NYSE : TEVA
Teva Announces Launch of its Generic Version of Canasa(R) (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 1000 mg strength generic version of Casana(R) 1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal
RHEA-AI
neutral
04/19/21 8:00 AM
NYSE : TEVA
New Clinical and Real-World Data Evaluating Efficacy of AJOVY(R) (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY (R) (fremanezumab-vfrm). These data are being presented at the 2021 American Academy of
RHEA-AI
neutral
04/15/21 8:00 AM
NYSE : TEVA
Teva to Present New Analyses of AJOVY(R) (fremanezumab-vfrm) Injection and AUSTEDO(R) (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva's Ongoing Commitment to Neurology
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced 19 presentations examining clinical and real-world data for AJOVY (R) (fremanezumab-vfrm) injection and AUSTEDO (R) (deutetrabenazine) tablets will be presented at the upcoming
RHEA-AI
neutral